RS53249B - Inhibitori cxcr1/2 kao adjuvansi u transplantaciji pankreasnih ostrvaca - Google Patents

Inhibitori cxcr1/2 kao adjuvansi u transplantaciji pankreasnih ostrvaca

Info

Publication number
RS53249B
RS53249B RS20140102A RSP20140102A RS53249B RS 53249 B RS53249 B RS 53249B RS 20140102 A RS20140102 A RS 20140102A RS P20140102 A RSP20140102 A RS P20140102A RS 53249 B RS53249 B RS 53249B
Authority
RS
Serbia
Prior art keywords
transplantation
reparixin
mice
inhibitor
cxcr1
Prior art date
Application number
RS20140102A
Other languages
English (en)
Serbian (sr)
Inventor
Lorenzo Piemonti
Luisa Daffonchio
Marcello Allegretti
Original Assignee
Dompé S.p.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompé S.p.A. filed Critical Dompé S.p.A.
Publication of RS53249B publication Critical patent/RS53249B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RS20140102A 2009-10-06 2010-10-06 Inhibitori cxcr1/2 kao adjuvansi u transplantaciji pankreasnih ostrvaca RS53249B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172364A EP2308484A1 (en) 2009-10-06 2009-10-06 Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
PCT/EP2010/064921 WO2011042466A1 (en) 2009-10-06 2010-10-06 Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Publications (1)

Publication Number Publication Date
RS53249B true RS53249B (sr) 2014-08-29

Family

ID=41818891

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20140102A RS53249B (sr) 2009-10-06 2010-10-06 Inhibitori cxcr1/2 kao adjuvansi u transplantaciji pankreasnih ostrvaca

Country Status (24)

Country Link
US (1) US20120202884A1 (https=)
EP (2) EP2308484A1 (https=)
JP (2) JP5834010B2 (https=)
KR (2) KR101759362B1 (https=)
CN (2) CN104906572A (https=)
AU (1) AU2010305385B2 (https=)
BR (1) BR112012007991B8 (https=)
CA (1) CA2775902C (https=)
CY (1) CY1115018T1 (https=)
DK (1) DK2485723T3 (https=)
EA (1) EA021298B1 (https=)
ES (1) ES2451349T3 (https=)
HK (1) HK1213777A1 (https=)
HR (1) HRP20140202T1 (https=)
IL (1) IL219037A (https=)
ME (1) ME01719B (https=)
MX (1) MX2012004082A (https=)
NZ (1) NZ599172A (https=)
PL (1) PL2485723T3 (https=)
PT (1) PT2485723E (https=)
RS (1) RS53249B (https=)
SI (1) SI2485723T1 (https=)
SM (1) SMT201400033B (https=)
WO (1) WO2011042466A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
CN103159652B (zh) * 2011-12-19 2016-06-08 天津市国际生物医药联合研究院 亚磺酰胺类化合物的制备及其应用
WO2014205127A2 (en) 2013-06-18 2014-12-24 New York University Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets
US11291641B2 (en) * 2016-10-03 2022-04-05 The Children's Medical Center Corporation Prevention and treatment of diabetic nephropathy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
AU2001253496A1 (en) * 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Treating graft rejection with cxcr3 inhibitors
US20020042370A1 (en) * 2000-04-14 2002-04-11 Millennium Pharmaceuticals, Inc. Method of treating graft rejection using inhibitors of CCR2 function
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
ATE444286T1 (de) 2004-03-23 2009-10-15 Dompe Pha R Ma Spa Res & Mfg 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung
PT1579859E (pt) 2004-03-25 2007-03-30 Dompe Pha R Ma Spa Res & Mfg Utilização de n-(2-aril-propionil)-sulfonamidas pata o tratamento de lesões da medula espinal
US20050261762A1 (en) * 2004-05-21 2005-11-24 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
EP1790637B1 (en) * 2004-09-13 2014-01-29 Ono Pharmaceutical Co., Ltd. Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient
JP5232144B2 (ja) * 2006-06-28 2013-07-10 サノフイ Ｃｘｃｒ２阻害剤
WO2008039876A1 (en) * 2006-09-26 2008-04-03 Case Western Reserve University Cytokine signaling
CN102088993A (zh) 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Also Published As

Publication number Publication date
CN104906572A (zh) 2015-09-16
JP2015145404A (ja) 2015-08-13
EA021298B1 (ru) 2015-05-29
IL219037A0 (en) 2012-06-28
KR101759362B1 (ko) 2017-07-18
PL2485723T3 (pl) 2014-07-31
BR112012007991A2 (pt) 2017-07-25
JP6097328B2 (ja) 2017-03-15
US20120202884A1 (en) 2012-08-09
CA2775902A1 (en) 2011-04-14
KR101817912B1 (ko) 2018-02-21
BR112012007991B1 (pt) 2020-12-15
CN102665703B (zh) 2016-04-20
ME01719B (me) 2014-09-20
SMT201400033B (it) 2014-07-07
EP2308484A1 (en) 2011-04-13
AU2010305385B2 (en) 2016-04-21
CN102665703A (zh) 2012-09-12
SI2485723T1 (sl) 2014-06-30
HK1175993A1 (zh) 2013-07-19
EP2485723B1 (en) 2013-12-11
JP2013506704A (ja) 2013-02-28
WO2011042466A1 (en) 2011-04-14
HRP20140202T1 (en) 2014-05-23
BR112012007991B8 (pt) 2021-05-25
JP5834010B2 (ja) 2015-12-16
CY1115018T1 (el) 2017-01-25
IL219037A (en) 2015-01-29
KR20170068625A (ko) 2017-06-19
PT2485723E (pt) 2014-03-13
CA2775902C (en) 2016-11-29
ES2451349T3 (es) 2014-03-26
NZ599172A (en) 2014-03-28
MX2012004082A (es) 2012-07-25
KR20120083440A (ko) 2012-07-25
HK1213777A1 (zh) 2016-07-15
AU2010305385A1 (en) 2012-04-26
EP2485723A1 (en) 2012-08-15
EA201270513A1 (ru) 2012-11-30
DK2485723T3 (en) 2014-03-17

Similar Documents

Publication Publication Date Title
EP1429845B1 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
NO338800B1 (no) Medikamenter med reduserende virkning på lymfocytter i det perifere kretsløp
RS53249B (sr) Inhibitori cxcr1/2 kao adjuvansi u transplantaciji pankreasnih ostrvaca
US12521419B2 (en) Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome
AU2002320828A1 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
AU2010305384B2 (en) Sulfonamides for the prevention of diabetes
Paty et al. * Islet Transplantation
Koike et al. Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect
EP3878443A1 (en) Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor
Cravedi et al. Successes and disappointments with clinical islet transplantation
HK1175993B (en) Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
Buemi Islet transplantation: cell therapy for type 1 diabetes
van den Berg Prolonged survival of rat islet xenografts in mice after CD45RB monotherapy
Faradji et al. METABOLIC EFFECTS OF EXENATIDE IN POST ISLET TRANSPLANT RECIPIENTS.
Froud et al. THE USE OF EXENATIDE TO IMPROVE ISLET ENGRAFTMENT, FUNCTION AND LONG TERM SURVIVAL.
Ciancio et al. A RANDOMIZED LONG-TERM TRIAL OF TACROLIMUS/SIROLIMUS VERSUS TACROLIMUS/MYCOPHENOLATE VERSUS CYCLOSPORINE (NEORAL®)/SIROLIMUS IN RENAL TRANSPLANTATION: THREE YEAR ANALYSIS.
Saudek et al. ANTI-THYMOCYTE GLOBULIN PRESERVES RESIDUAL C-PEPTIDE PRODUCTION UN TYPE-1 DIABETES OF RECENT ONSET.